NL-OMON28317招募中不适用
A phase 0 single dose study to evaluate the pharmacokinetics/-dynamics and specific targeting properties of 124-I-F8IL10 in patients with active rheumatoid arthritis.
VU University Medical Center0 个研究点目标入组 5 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 5
研究概览
简要总结
/A
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •1. Patients aged ≥18 years;
- •2. Diagnosis of RA according to ACR criteria;
排除标准
- •1. Presence of active infections (e.g. requiring antibiotic therapy) or other severe concurrent disease, which, in the opinion of the investigator, would place the patient at undue risk or interfere with the study;
- •2. Chronic active hepatitis (hepatitis B/C) or active autoimmune diseases other than RA;
研究者
相似试验
已完成
1 期
A study in healthy volunteers to investigate how the test medicine CORT113176 is taken up by the body when given with food and without foodAmyotrophic lateral sclerosis (ALS)Nervous System DiseasesMotor neuron diseaseISRCTN52169163Corcept Therapeutics (United States)35
已完成
不适用
A PHASE 0 SINGLE DOSE STUDY TO EVALUATE THE PHARMACOKINETICS/-DYNAMICS AND SPECIFIC TARGETING PROPERTIES OF 124-I-F8IL10 IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND INFLAMMATORY BOWEL DISEASErheumatoid arthritis and inflammatory bowel disease100179691000381610023213NL-OMON39620Vrije Universiteit Medisch Centrum10
已完成
1 期
A pharmacokinetic study of novel formulations of ISC 17536 in healthy male adultsCTRI/2020/09/028094Glenmark Pharmaceuticals Ltd108
已完成
1 期
A Study to Evaluate the Pharmacokinetics of VI-0521 in Subjects With Hepatic ImpairmentHepatic ImpairmentNCT00768209VIVUS LLC18
已完成
1 期
Oral Remimazolam With and Without Alcohol in Healthy Female SubjectsSafety IssuesNCT04113343Paion UK Ltd.21